Clinical trials: Semaglutide, completed
Diabetes
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors
This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the…
- Trial name
- NCT05768945
- Testing
- Semaglutide, DPP-4 inhibitor
- Where
- United States
- Volunteers
- 742,670 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Pneumonia, Aspiration, Anesthesia
Evaluation of Gastric Content of Volunteers Fasting and Using Semaglutide: an Observational and Cross-sectional Study
Medicines with peptide-1 receptor agonist action similar to glucagon (GLP-1) are a modern therapeutic option for obesity and diabetes mellitus.
- Trial name
- NCT06154486
- Testing
- semaglutide use
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Hospital Israelita Albert Einstein
Type 1 Diabetes, Diabetes Mellitus, Type 1
Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care
A closed-loop insulin system, also referred to as the "artificial pancreas" (AP), is made up of an insulin pump, a continuous glucose monitor, and an application communicating between the two to adjust insulin administration…
- Trial name
- SEMA-AP (NCT05205928)
- Testing
- Outpatient therapy: 11 weeks of drug therapy with usual treatment + 4 weeks of closed-loop therapy
- Where
- Canada
- Volunteers
- 28 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Metabolic Disease
Efficacy of Semaglutide in Glycemic Control, Weight Loss, and Improving Lipidogram- Role of Baseline Vitamin D Levels
Objective: Semaglutide, a glucagon-like peptide-1 receptor agonist, is an established therapy for type 2 diabetes (T2D), offering robust glycemic control and weight reduction.
- Trial name
- Semaglutide (NCT07043361)
- Testing
- semaglutide
- Where
- Israel
- Volunteers
- 5,300 people
- Sponsor
- Hillel Yaffe Medical Center
Obesity / Overweight
A Study Comparing the Effects of BGM0504 Injection and Semaglutide Injection on Obese Subjects.
An Investigator-Initiated, Randomized, Open-Label, Active-Controlled Study Comparing the Effects of BGM0504 Injection versus Semaglutide Injection on Insulin Sensitivity and Body Weight in Obese Subjects
- Trial name
- NCT07836140
- Testing
- semaglutide, BGM0504 Administered SC
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Second Affiliated Hospital of Soochow University
Overweight and Obesity, Type2diabetes
Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant
The purpose of this study is to evaluate the safety, tolerability and drug levels of an exenatide implant administered subcutaneously.
- Trial name
- LIBERATE-1 (NCT05670379)
- Testing
- Exenatide Implant, Bydureon BCise (exenatide extended release), Semaglutide, 1.0 mg/mL
- Where
- Australia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Vivani Medical, Inc
Overweight, Obesity
Real-World Patient and Physician Experience With Semaglutide Across Six Emerging Markets
The purpose of this study is to assess semaglutide's impact on daily life from participants and physicians experience.
- Trial name
- NCT07850765
- Testing
- Semaglutide
- Where
- 6 sites in Israel, Mexico and 4 more
- Volunteers
- 1,260 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Healthy
Investigating the Pharmacokinetics of Subcutaneous Injections With 1 mg/mL, 3 mg/mL, and 10 mg/mL Semaglutide Strengths and the Absolute Bioavailability of Semaglutide
This trial is conducted in Europe. The aim of this trial is to investigate the pharmacokinetics (the exposure of the trial drug in the body) of subcutaneous injections of three different strengths of semaglutide and the absolute…
- Trial name
- NCT02231684
- Testing
- semaglutide
- Where
- Germany
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity
Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes
This study looks at how well a new medicine, called semaglutide, works at helping people with obesity and prediabetes. This study will look at how much weight participants lose, and if participants can go from having blood sugar…
- Trial name
- STEP 10 (NCT05040971)
- Testing
- Semaglutide 2.4 mg
- Where
- 43 sites in Canada, Denmark and 3 more
- Volunteers
- 207 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice
The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower participants blood sugar levels.
- Trial name
- PIONEER REAL (NCT04559815)
- Testing
- Oral Semaglutide
- Where
- 2 sites in Canada
- Volunteers
- 194 people
- Sponsor
- Novo Nordisk A/S
HIV Infections, Non-Alcoholic Fatty Liver Disease
Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)
The purpose of this study was to evaluate the effects of semaglutide on intra-hepatic triglyceride (IHTG) content in people living with HIV (PLWH), central adiposity, insulin resistance or pre-diabetes, and hepatic steatosis.
- Trial name
- NCT04216589
- Testing
- Semaglutide
- Where
- 9 sites in United States, Brazil
- Volunteers
- 51 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Diabetes Mellitus, Type 2
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice (SURE GERMANY)
The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed by their study doctor. The study will last for about 6 to 8 months.
- Trial name
- SURE GERMANY (NCT04261933)
- Testing
- semaglutide
- Where
- 95 sites in Germany
- Volunteers
- 789 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes.
This trial is conducted in Europe. The aim of this trial is, to investigate the effect of upper gastrointestinal disease on the pharmacokinetics (the exposure of the trial drug in the body) of oral semaglutide in subjects with…
- Trial name
- NCT02877355
- Testing
- semaglutide
- Where
- 2 sites in Germany
- Volunteers
- 55 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects
The aim of the study is to investigate the effect of the medicines, probenecid and ciclosporin on the concentrations of SNAC. SNAC is an ingredient of the semaglutide tablets.
- Trial name
- NCT03466567
- Testing
- Semaglutide, Probenecid, Ciclosporin
- Where
- Germany
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes
The study compares 2 medicines for type 2 diabetes: oral semaglutide (a new medicine) and placebo (a dummy medicine). Researchers will test semaglutide to see how well it works compared to placebo.
- Trial name
- PIONEER 11 (NCT04109547)
- Testing
- Oral semaglutide
- Where
- 66 sites in Algeria, China and 4 more
- Volunteers
- 521 people
- Sponsor
- Novo Nordisk A/S
Obesity &Amp; Overweight
Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment
This clinical study investigates how blocking the hunger-related ghrelin receptor affects appetite and metabolism in individuals with obesity who are treated with semaglutide (a GLP-1 receptor agonist).
- Trial name
- SILENCED (NCT07171723)
- Testing
- Liver-Expressed Antimicrobial Peptide 2 (LEAP2)
- Where
- Denmark
- Volunteers
- 24 people
- Sponsor
- University Hospital, Gentofte, Copenhagen
Metabolic Dysfunction-Associated Steatohepatitis (MASH), Obesity
Efficacy and Safety of CS0159 Combined With Semaglutide in MASH Patients With Obesity and T2DM
This is an exploratory study evaluating CS0159 in combination with Semaglutide in MASH patients with obesity and T2DM.
- Conditions
- Metabolic Dysfunction-Associated Steatohepatitis (MASH), Obesity, Diabetes Mellitus, Type 2
- Trial name
- NCT06492330
- Testing
- CS0159
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Alcohol Use Disorder
Semaglutide Therapy for Alcohol Reduction - Tulsa
The purpose of this research study is to determine if semaglutide, when compared to placebo, is safe and may reduce alcohol drinking in individuals who endorse symptoms consistent with alcohol use disorder.
- Trial name
- STAR-T (NCT05891587)
- Testing
- Semaglutide
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Oklahoma State University Center for Health Sciences
Obesity
A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight
This study will look at how CagriSema affects the blood levels of atorvastatin and warfarin. The study will look at the levels of warfarin and atorvastatin in the blood before the participant starts taking CagriSema and if this…
- Trial name
- NCT06289504
- Testing
- Cagrilintide, Semaglutide, Atorvastatin
- Where
- Canada
- Volunteers
- 34 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects
This trial is conducted in Asia. The aim of the trial is to investigate the pharmacokinetics (the exposure of the trial drug in the body), pharmacodynamics (the effect of the investigated drug on the body), and the safety and…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT02146079
- Testing
- semaglutide
- Where
- Japan
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S